Dual inhibition of the angiotensin receptor and neprilysin – revolutionary principle of treatment of chronic heart failure with reduced left ventricular ejection fraction

Česká verzia

Authors: F. Málek
Authors place of work: Kardiocentrum, Nemocnice Na Homolce, Praha
Published in the journal: Kardiol Rev Int Med 2016, 18(4): 281-286

Summary

Results of a PARADIGM-HF study (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) were presented and published in 2014. The study showed favourable effect of a new drug group represented by sacubitril-valsartan on the outcome of patients with chronic heart failure with reduced ejection fraction. Drug with original code LCZ696 comprised of sacubitril – neprilysin inhibitor, and AT1 angiotensin II receptor blocker valsartan. Sacubitril-valsartan is an example of a new drug group entitled: angiotensin receptor neprilysin inhibitor.

Keywords:
chronic heart silure - mortality – angiotensin II – neprilysin – sacubitril-valsartan

Zdroje

1. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart silure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(27): 2129– 2200. doi: 10.1093/ eurheartj/ ehw128.

2. Hradec J, Vítovec J, Špinar J. Souhrn Doporučených postupů ESC pro diagnostiku a léčbu srdečního selhání 2012. Cor Vasa 2013; 55: e25– e40.

3. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316(23): 1429– 1435.

4. Rogers WJ, Johnstone DE, Yusuf S et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293– 302. doi: 10.1056/ NEJM199108013250501.

5. Pfeffer MA, Braunwald E, Moye LA et al. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327(10): 669– 677.

6. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875): 821– 828.

7. CIBIS Investigators and Commities. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Lancet 1999; 353(9146): 9– 13.

8. MERIT-HF Study Group. Effect of metoprolol CR/ XL in chronic heart failure. Metoprolol CR/ XL randomised intervention trial in congestive heart failure. Lancet 1999; 353(9169): 2001– 2007.

9. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22): 1651– 1658.

10. Flather MD, Shibata MC, Coats AJ et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215– 225.

11. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709– 717.

12. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11– 21. doi: 10.1056/ NEJMoa1009492.

13. Swedberg K, Komajda M, Bohm M et al. Ivabradin and outcomes in chronic heart failure(SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376(9744): 875– 885. doi: 10.1016/ S0140-6736(10)61198-1.

14. McMurray JJ, Packer M, Desai AS et al. Angiotensin neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993– 1004. doi: 10.1056/ NEJMoa1409077.

15. Wilkins MR, Redondo J. The natriuretic peptide-family. Lancet 1997; 349(9061): 1307– 1310.

16. Bonow RO. New insights into the cardiac natriuretic peptides. Circulation 1996; 93(11): 1946– 1950.

17. Grantham JA, Burnett JC jr. BNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation 1997; 96(2): 388– 390.

18. De Bold AJ. Heart atria granularity: effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979; 161(4): 508– 511.

19. Suga S, Nakao K, Hosoda K et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130(1): 229– 239.

20. Maack T, Suzuki M, Almeida FA et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238(4827): 675– 678.

21. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system inchronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96(2): 509– 516.

22. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84(4): 1581– 1588.

23. Marcus LS, Hart D, Packer M et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1996; 94(2): 3184– 3189.

24. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343(4): 264– 253.

25. Margulies KB, Barclay PL, Burnett JC jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91(7): 2036– 2042.

26. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356(9230): 615– 620.

27. Packer M, Califf RM, Konstam MA et al. OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart silure. Circulation 2002; 106(8): 920– 926.

28. SPC Entresto. Dostupné z: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/004062/WC500197536.pdf.

29. Solomon SD, Ziele M, Pieske B et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: (9851):1387– 1395. doi: 10.1016/ S0140-6736(12)61227-6.

30. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF) Available from: https://clinicaltrials.gov/ct2/show/NCT01920711.